What's Behind ARCH Venture Management's Reduced Stake in Maze Therapeutics

Related Articles

What Does BlackRock's Reduced Stake in Orion Corporation Signify

4 months ago

What's Driving the Surge in Analyst Confidence for Venture Global (VG)

6 months ago

What's Behind Acadian Asset Management's Recent Surge

6 months ago

What Does Senator Hagerty's Venture Capital Investment Signal

6 months ago

Category

You may also like

Stock News•1 week ago

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

Standard BioTools agreed to sell its Microfluidics business to healthcare investor ARCHIMED, reshaping the company's portfolio. Terms and timing were not disclosed, leaving valuation and proceeds unce...

LAB

Share

Stock News•1 months ago

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Maze Therapeutics CMO Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026, equal to 100% of his directly held common stock before the filing.

MAZE

Share

Stock News•3 months ago

AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study

AstraZeneca shares fell after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising doubts about its expansion into a larger market.

AZN

Share